DTI Tightens Monitoring on Vape Shops in Manila

Jun.08.2023
DTI Tightens Monitoring on Vape Shops in Manila
DTI tightens monitoring of e-cigarette shops in Manila to ensure compliance with vape regulation laws.

On June 8th, according to the Philippine News Agency, Fred Pascual, the Secretary of the Department of Trade and Industry (DTI) of the Philippines, ordered the strengthening of monitoring of e-cigarette shops in the National Capital Region (NCR) to ensure compliance with sales restrictions outlined in the Vaporized Nicotine and Non-Nicotine Products Regulation Act. DTI has monitored a total of 29,167 shops, including 583 physical stores and 28,584 online stores.


Minister Pascal of the Department of Trade and Industry stated:


The Department of Trade and Industry, through its Fair Trade Enforcement Bureau (FTEB), will continue to enhance its monitoring of these businesses. The goal is to ensure a balance between the interests of the companies/manufacturers while protecting the youth from the harmful effects of these substances.


As of June 1st, DTI has monitored a total of 29,167 stores, including 583 physical stores and 28,584 online shops.


Out of the 583 physical stores monitored, 229 were found to be compliant while 214 were not. On the other hand, only 175 out of 28,584 online stores that underwent physical inspections were compliant, while 2,809 were found to be non-compliant. An additional 26,986 online stores are currently undergoing physical inspections.


Based on the monitoring results stated above, the Fair Trade Enforcement Bureau (FTEB) has issued violation notices/reasons for non-compliance to 72 businesses. The Department of Trade and Industry (DTI) also seized 13,784 products from non-compliant shops, with a retail value of approximately 4.25 million Philippine pesos (equivalent to around 540,000 yuan).


The vast majority of companies that have received notice letters for reasons of non-compliance are engaged in the following violations:


The fourth regulation pertains to the packaging requirements for products. The fifth regulation pertains to the sale of nicotine and non-nicotine products, as well as their equipment or new tobacco products. The sixth regulation pertains to restrictions on the dissemination, advertising, and sponsorship of products. The eighth regulation prohibits the use of vape products in public places. As of June 1st, the DTI's adjudication department has received 74 formal charges, with 73 against physical stores and 1 against an online store. The DTI is monitoring major social media and e-commerce platforms to ensure that minors cannot purchase these substances online.


The Philippines has recently intensified its crackdown on illegal e-cigarettes, targeting both brick-and-mortar stores and online retailers. This comes after the passage of the Vaporous Nicotine and Non-Nicotine Products Regulation Act in 2022, which aims to regulate the import, manufacturing, sale, packaging, distribution, use and dissemination of vaporized nicotine and non-nicotine products (including e-cigarettes) and new tobacco products.


The Department of Trade and Industry (DTI) has mandated stricter supervision of vaporizer shops in the metropolitan area of Manila.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
CCPIT Says Trade Friction Index for China-Related Electronics Sector Remains High, With Vape Products Among Areas of Focus
CCPIT Says Trade Friction Index for China-Related Electronics Sector Remains High, With Vape Products Among Areas of Focus
China Council for the Promotion of International Trade (CCPIT) held its July regular press conference on July 31, 2026, releasing the May 2026 Global Economic and Trade Friction Index. CCPIT spokesperson Yang Fan said the global trade friction index stood at 95 in May, remaining at a medium-to-high level. By industry, the electronics sector recorded the highest trade friction index among 13 monitored industries. In China-related trade frictions, the index stood at 93, with electronics products including drones, chips and vape products among areas where friction remained elevated.
Aug.03
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
The UK Insolvency Service said YSK Enterprises imported large quantities of vapes from China in 2023, with a shipment addressed to the company declared as medical nebulizers before Border Force found 352,688 vaping products. HMRC calculated nearly £15 million ($20.3 million) in unpaid VAT and customs duty, alongside about £437,000 in corporation tax. Two directors were disqualified for nine years. The case predates the UK's Vaping Products Duty, which will introduce vape-specific excise and duty-stamp requirements from October 2026.
Regulations
Sep.11
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11